Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01CNB
|
|||
| Former ID |
DNCL003524
|
|||
| Drug Name |
E6201
|
|||
| Synonyms |
novel MEK inhibitors
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [1], [2] | |
| Company |
Eisai Ltd.
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C21H27NO6
|
|||
| Canonical SMILES |
CCNC1=CC2=C(C(=C1)O)C(=O)OC(C(C=CC(=O)C(C(CC=C2)O)O)C)C
|
|||
| InChI |
1S/C21H27NO6/c1-4-22-15-10-14-6-5-7-16(23)20(26)17(24)9-8-12(2)13(3)28-21(27)19(14)18(25)11-15/h5-6,8-13,16,20,22-23,25-26H,4,7H2,1-3H3/b6-5+,9-8-/t12-,13+,16+,20+/m1/s1
|
|||
| InChIKey |
MWUFVYLAWAXDHQ-HMNLTAHHSA-N
|
|||
| CAS Number |
CAS 603987-35-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7836). | |||
| REF 2 | ClinicalTrials.gov (NCT02418000) A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation. U.S. National Institutes of Health. | |||
| REF 3 | E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther. 2010 Oct;335(1):23-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.